CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Find out why stress can worsen allergy symptoms. Learn about the cellular chain reaction that occurs in the body and how it ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

SeaStar Medical plans to conduct an interim analysis at the trial’s 90-day primary endpoint with the first 100 subjects. Given the current pace of enrollment, the company anticipates a Data Safety ...

Discover how atopic dermatitis, an allergic skin condition characterised by inflammation and heightened IgE levels, is often ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

DHEA is a steroid hormone produced in several organs of the body including the adrenal gland, gonads, and brain.